计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G126512-1mg |
1mg |
现货 ![]() |
| |
| G126512-5mg |
5mg |
现货 ![]() |
| |
| G126512-25mg |
25mg |
现货 ![]() |
| |
| G126512-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | MFCD26142930 | 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide | Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b) |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | GZD824 |
| 生化机理 | 说明:IC50值:0.2 nM [1]GZD824是一种新型生物活性抑制剂,可抑制包括T315I在内的多种Bcr-Abl突变体。GZD824 与 Bcr-Abl(WT)和 Bcr-Abl(T315I)紧密结合,体外 K(d) 值分别为 0.32 和 0.71 nM:GZD824 能有效抑制 Bcr-Abl 阳性的 K562 和 Ku812 人 CML 细胞的增殖,IC(50) 值分别为 0.2 和 0.13 nM。在体内:GZD824能诱导Bcr-Abl(WT)或突变体驱动的小鼠异种移植肿瘤模型中的肿瘤消退,并能显著提高携带Bcr-Abl(T315I)的Ba/F3细胞的异种移植白血病模型小鼠的存活率[1]:临床试验:GZD824 尚处于未知临床状态。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | Bcr/Abl 融合蛋白抑制剂 |
| 产品介绍 |
GZD824是新型的Bcr-Abl野生型和T315I突变型抑制剂,IC50分别为0.34和0.68nM。 GZD824 is a novel bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively. |
| 纯度 | ≥98% |
| ALogP | 4.6 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide |
| INCHI | 1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36) |
| InChi Key | TZKBVRDEOITLRB-UHFFFAOYSA-N |
| Smiles | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4 |
| Isomeric SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4 |
| 分子量 | 532.56 |
| Reaxy-Rn | 23359312 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23359312&ln= |
| 溶解性 | 25°C: DMSO |
|---|---|
| 分子量 | 532.600 g/mol |
| XLogP3 | 4.600 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 532.22 Da |
| 单同位素质量Monoisotopic Mass | 532.22 Da |
| 拓扑极表面积Topological Polar Surface Area | 77.200 Ų |
| 重原子数Heavy Atom Count | 39 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 910.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al.. (2013) Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.. J Med Chem, 56 (3): (879-94). [PMID:23301703] |
| 2. Liu X, Wang G, Yan X, Qiu H, Min P, Wu M, Tang C, Zhang F, Tang Q, Zhu S et al.. (2019) Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.. Cell Biosci, 9 (88). [PMID:31673329] |
| 3. Dhillon S. (2022) Olverembatinib: First Approval.. Drugs, 82 (4): (469-475). [PMID:35195876] |
| 4. Chan M, Holland EC, Gujral TS. (2022) Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release in human peripheral blood mononuclear cells.. EMBO Mol Med, 14 (6): (e15919). [PMID:35579119] |